Literature DB >> 23307290

Natalizumab therapy for multiple sclerosis.

Jeremy Chataway1, David H Miller.   

Abstract

The treatment of relapsing remitting multiple sclerosis has witnessed major progress since the first effective disease modifying treatment, ß-interferon, became available in 1993. One of the most remarkable new treatments has been natalizumab. This review describes the evolution of this humanized anti-α4ß1 monoclonal antibody, from preclinical experimental research through proof-of-concept (phase 1/2) and pivotal (phase 3) clinical trials to the now extensive experience of its use in clinical practice. The future potential and challenges of natalizumab and oral therapies with a similar mechanism of action are also discussed.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23307290      PMCID： PMC3557363          DOI： 10.1007/s13311-012-0171-4

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


  47 in total

1.  Ocular toxoplasmosis during natalizumab treatment.

Authors:  Chiara Zecca; Fabio Nessi; Enos Bernasconi; Claudio Gobbi
Journal:  Neurology       Date:  2009-09-23       Impact factor: 9.910

Review 2.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

3.  Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis.

Authors:  S Gutwinski; S Erbe; C Münch; O Janke; U Müller; J Haas
Journal:  Neurology       Date:  2010-02-09       Impact factor: 9.910

4.  Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Authors:  Ernst-Wilhelm Radue; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Richard A Rudick; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Elizabeth Fisher; Athina Papadopoulou; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  J Neurol Sci       Date:  2010-03-16       Impact factor: 3.181

Review 5.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

6.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Authors:  B O Khatri; S Man; G Giovannoni; A P Koo; J-C Lee; B Tucky; F Lynn; S Jurgensen; J Woodworth; S Goelz; P W Duda; M A Panzara; R M Ransohoff; R J Fox
Journal:  Neurology       Date:  2009-02-03       Impact factor: 9.910

7.  Primary central nervous system lymphoma in a patient treated with natalizumab.

Authors:  Andreas Schweikert; Marcus Kremer; Florian Ringel; Thomas Liebig; Justus Duyster; Olaf Stüve; Bernhard Hemmer; Achim Berthele
Journal:  Ann Neurol       Date:  2009-09       Impact factor: 10.422

8.  GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.

Authors:  A D Goodman; H Rossman; A Bar-Or; A Miller; D H Miller; K Schmierer; F Lublin; O Khan; N M Bormann; M Yang; M A Panzara; A W Sandrock
Journal:  Neurology       Date:  2009-03-03       Impact factor: 9.910

9.  Seroepidemiology of human polyomaviruses.

Authors:  Jaime M Kean; Suchitra Rao; Michael Wang; Robert L Garcea
Journal:  PLoS Pathog       Date:  2009-03-27       Impact factor: 6.823

10.  Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML).

Authors:  Shamil R Sunyaev; Alexey Lugovskoy; Kenneth Simon; Leonid Gorelik
Journal:  PLoS Genet       Date:  2009-02-06       Impact factor: 5.917
View more
  8 in total

Review 1.  The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.

Authors:  Ron Milo
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

Review 2.  [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors:  L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

3.  Natalizumab-Related Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Case Report Highlighting Clinical and MRI Features.

Authors:  Bela Purohit; Eranga Ganewatte; Spyros S Kollias
Journal:  Malays J Med Sci       Date:  2016-10-05

4.  Endothelial Cell Insulin Signaling Regulates CXCR4 (C-X-C Motif Chemokine Receptor 4) and Limits Leukocyte Adhesion to Endothelium.

Authors:  Thomas Rathjen; Britta Kunkemoeller; Carly T Cederquist; Xuanchun Wang; Sam M Lockhart; James C Patti; Hanni Willenbrock; Grith Skytte Olsen; Gro Klitgaard Povlsen; Hans Christian Beck; Lars Melholt Rasmussen; Qian Li; Kyoungmin Park; George L King; Christian Rask-Madsen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-06-02       Impact factor: 10.514

Review 5.  Defining and scoring response to IFN-β in multiple sclerosis.

Authors:  Maria Pia Sormani; Nicola De Stefano
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

6.  Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.

Authors:  Massimiliano Castellazzi; Serena Delbue; Francesca Elia; Matteo Gastaldi; Diego Franciotta; Roberta Rizzo; Tiziana Bellini; Roberto Bergamaschi; Enrico Granieri; Enrico Fainardi
Journal:  Dis Markers       Date:  2015-05-26       Impact factor: 3.434

Review 7.  Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.

Authors:  Milan Buc
Journal:  Mediators Inflamm       Date:  2013-05-12       Impact factor: 4.711

8.  Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.

Authors:  Massimiliano Castellazzi; Tiziana Bellini; Alessandro Trentini; Serena Delbue; Francesca Elia; Matteo Gastaldi; Diego Franciotta; Roberto Bergamaschi; Maria Cristina Manfrinato; Carlo Alberto Volta; Enrico Granieri; Enrico Fainardi
Journal:  Dis Markers       Date:  2016-06-02       Impact factor: 3.434
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.